Premature T cell aging and vaccine failure in chronic viral infection

慢性病毒感染中 T 细胞过早衰老和疫苗失败

基本信息

  • 批准号:
    9023117
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-04-01 至 2020-03-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant) The overall goal of this proposal is to elucidate the mechanisms by which chronic viral infection mediates premature T cell aging and vaccine failure through regulation of microRNA-regulated proteins, with an aim to develop effective approaches to improve vaccine efficacy in virus-infected individuals. To this end, we will use a model of hepatitis B virus (HBV) vaccine failure i the setting of chronic hepatitis C virus (HCV) infection. The proposal is based on the fact that co-infection of HBV with HCV is common due to shared risk factors, and as such HBV vaccine is required to prevent super-infection and its associated increase in morbidity and mortality; however, vaccine responses in virus-infected individuals are often blunted. This phenomenon is also observed in the elderly who frequently fail to respond to vaccinations; and attempts to improve the rate of immunizations in both infected and aged populations have been unsuccessful, in part due to our poor understanding of the mechanisms that inhibit vaccine responses in these settings. In studying the effect of chronic viral infection on T cell functions, we and others have recently found that chronic HCV infection leads to T cell dysfunction mediated through up-regulation of aging markers, including killer cell lectin-like receptor subfamily G member 1 (KLRG1) and dual specific phosphatase 6 (DUSP6), concomitant with a decline of microRNA-155 (miR155) levels in CD4 T cells. Remarkably, these alterations are associated with impaired CD4 T cell functions in HCV- infected individuals and are more prominent in HBV vaccine non-responders (HBV-NR) compared to age- matched HBV vaccine responders (HBV-R). It has been demonstrated that with increasing age, KLRG1 is up- regulated and leads to inhibition of T cell receptor (TCR) signaling; whereas DUSP6 is increased and leads to recalibration of the TCR activation threshold; and miR155 decline is known to permit translation of a set of target genes related to T cell inhibition. However, the mechanisms underlying miR155/KLRG1/DUSP6 expression and regulation of premature T cell aging and vaccine responses during HCV infection remain unknown. In this proposal, we hypothesize that HCV-induced loss of miR155 mediates premature T cell aging by up-regulating KLRG1 and/or DUSP6 expressions, such that targeting these inhibitory pathways may rescue impaired CD4 T cell functions and subsequently boost blunted vaccine responses in virus-infected individuals. To test this hypothesis, we will carry out the following two specific aims: Aim 1 will define the transcriptional and translational mechanisms that control miR155 expression and the role of miR155 in regulating KLRG1 and/or DUSP6 expression in T cells during HCV infection; Aim 2 will examine the consequences of miR155 loss and KLRG1/DUSP6 over-expression in T cell function and vaccine response in virus-infected individuals. This translational study is significant in that it provides a working model to explore mechanisms that may be fundamental to diminished vaccine responses in general, particularly in the setting of immunocompromise by HIV, hemodialysis, transplantation, and cancer.


项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Zhi Q. Yao其他文献

Zhi Q. Yao的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Zhi Q. Yao', 18)}}的其他基金

Dual specific gene editing drugs delivered by nanoparticles targeting HBV/HIV coinfection
针对 HBV/HIV 双重感染的纳米颗粒递送的双特异性基因编辑药物
  • 批准号:
    10403587
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
HIV infection-induced mitochondrial dysfunction and premature T cell aging
HIV感染引起的线粒体功能障碍和T细胞过早衰老
  • 批准号:
    10203459
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Mitochondrial Dysfunction in Aging CD4 T cells in HIV-immune Non-responders.
HIV 免疫无反应者中衰老 CD4 T 细胞的线粒体功能障碍。
  • 批准号:
    10845843
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Dual specific gene editing drugs delivered by nanoparticles targeting HBV/HIV coinfection
针对 HBV/HIV 双重感染的纳米颗粒递送的双特异性基因编辑药物
  • 批准号:
    10161447
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Multiuser Advanced Confocal Microscope
多用户高级共焦显微镜
  • 批准号:
    9791445
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Telomere loss and T cell aging in HBV vaccine response in HCV-infected individual
HCV 感染者的 HBV 疫苗反应中的端粒丢失和 T 细胞老化
  • 批准号:
    10265317
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Telomere loss and T cell aging in HBV vaccine response in HCV-infected individual
HCV 感染者的 HBV 疫苗反应中的端粒丢失和 T 细胞老化
  • 批准号:
    10455526
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Gender difference in miRNA-mediated T cell aging during viral infection
病毒感染期间 miRNA 介导的 T 细胞衰老的性别差异
  • 批准号:
    9896225
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
ShEEP Proposal for a Multiuser Advanced Biosafe Flow Cytometer
ShEEP 针对多用户高级生物安全流式细胞仪的提案
  • 批准号:
    9211532
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
Telomere attrition and T cell aging in vaccine failure during HIV infection
HIV 感染期间疫苗失败时的端粒磨损和 T 细胞老化
  • 批准号:
    10581156
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Mechanistic insights into multifaceted roles of coronavirus exoribonuclease complex
冠状病毒外核糖核酸酶复合物多方面作用的机制见解
  • 批准号:
    10713523
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Novel Function(s) of Arenavirus NP Exoribonuclease
Arenavirus NP 核糖核酸外切酶的新功能
  • 批准号:
    10525101
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Novel Function(s) of Arenavirus NP Exoribonuclease
Arenavirus NP 核糖核酸外切酶的新功能
  • 批准号:
    10624457
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Characterizing the XRN1 exoribonuclease as a therapeutic target in non-small cell lung cancer
将 XRN1 核糖核酸外切酶表征为非小细胞肺癌的治疗靶点
  • 批准号:
    10215766
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Exploring the Coronavirus Exoribonuclease as an Antiviral Target
探索冠状病毒外核糖核酸酶作为抗病毒靶点
  • 批准号:
    10238324
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Characterizing the XRN1 exoribonuclease as a therapeutic target in non-small cell lung cancer
将 XRN1 核糖核酸外切酶表征为非小细胞肺癌的治疗靶点
  • 批准号:
    10656174
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Characterizing the XRN1 exoribonuclease as a therapeutic target in non-small cell lung cancer
将 XRN1 核糖核酸外切酶表征为非小细胞肺癌的治疗靶点
  • 批准号:
    10370384
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Exploiting the SARS-CoV-2 nsp14 3'-5'-exoribonuclease as a target for antiviral chemotherapy
利用 SARS-CoV-2 nsp14 3-5-核糖核酸外切酶作为抗病毒化疗的靶点
  • 批准号:
    MR/V036904/1
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
    Research Grant
Dissecting the role of the coronavirus proofreading exoribonuclease in RNA recombination
剖析冠状病毒校对核糖核酸酶在 RNA 重组中的作用
  • 批准号:
    10268982
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Flow responsive endothelial Pnpt1: an exoribonuclease that regulates mitochondrial function and vascular disease
流量响应内皮 Pnpt1:一种调节线粒体功能和血管疾病的核糖核酸外切酶
  • 批准号:
    9750410
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了